Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: Scavenging free heme to preserve vasculature homeostasis

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Vinchi, Francesca ^a   Tolosano, Emanuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTIONS; BENEFICIAL EFFECTS; CARDIOVASCULAR FUNCTION; ENDOTHELIAL DYSFUNCTION; PATHOLOGIC CONDITIONS; SURGICAL PROCEDURES; VASCULAR ENDOTHELIUM; VASCULAR FUNCTIONS;

BIOCHEMISTRY; BLOOD; DIALYSIS; DIGITAL STORAGE; HEMOGLOBIN; NITRIC OXIDE; PATHOLOGY; SCAVENGING;

PORPHYRINS;

ANTIOXIDANT; CELL ADHESION MOLECULE; ERYTHRITOL; GLUTAMINE; HEME; HEMOGLOBIN; HEMOPEXIN; HYDROXAMIC ACID; NICOTINIC ACID; SCAVENGER;

BIOAVAILABILITY; CARDIOVASCULAR FUNCTION; ENDOTHELIAL DYSFUNCTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HOMEOSTASIS; IMMUNIZATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN SECRETION; REVIEW; THROMBOSIS; VASCULAR DISEASE; VASCULARIZATION; ANIMAL; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

BACTERIA (MICROORGANISMS);

ANIMALS; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; HEME; HEMOLYSIS; HEMOPEXIN; HOMEOSTASIS; HUMANS;

EID: 84879347493     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/396527     Document Type: Review

References (104)

1. Dhaliwal G., Cornett P. A., Tierney L. M., Hemolytic anemia. American Family Physician 2004 69 11 2599 2606 2-s2.0-2642553176
2. Gozzelino R., Jeney V., Soares M. P., Mechanisms of cell protection by heme oxygenase-1. Annual Review of Pharmacology and Toxicology 2010 50 323 354 2-s2.0-77949525185 10.1146/annurev.pharmtox.010909.105600
3. Meyer C., Heiss C., Drexhage C., Kehmeier E. S., Balzer J., Mühlfeld A., Merx M. W., Lauer T., Kühl H., Floege J., Kelm M., Rassaf T., Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. Journal of the American College of Cardiology 2010 55 5 454 459 2-s2.0-74549121338 10.1016/j.jacc.2009.07.068
4. Tolosano E., Fagoonee S., Morello N., Vinchi F., Fiorito V., Heme scavenging and the other facets of hemopexin. Antioxidants & Redox Signaling 2010 12 2 305 320 2-s2.0-77949497609 10.1089/ars.2009.2787
5. Schaer D. J., Buehler P. W., Alayash A. I., Belcher J. D., Vercellotti G. M., Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013 121 1276 1284 10.1182/blood-2012-11-451229
6. Morgan W. T., The binding and transport of heme by hemopexin. Annals of Clinical Research 1976 8 supplement 17 223 232 2-s2.0-0017198426
7. Morgan W. T., Liem H. H., Sutor R. P., Muller Eberhard U., Transfer of heme from heme albumin to hemopexin. Biochimica et Biophysica Acta 1976 444 2 435 445 2-s2.0-0017158738
8. Vinchi F., Gastaldi S., Silengo L., Altruda F., Tolosano E., Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload. American Journal of Pathology 2008 173 1 289 299 2-s2.0-46749135674 10.2353/ajpath.2008.071130
9. Seixas E., Gozzelino R., Chora A., Ferreira A., Silva G., Larsen R., Rebelo S., Penido C., Smith N. R., Coutinho A., Soares M. P., Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proceedings of the National Academy of Sciences of the United States of America 2009 106 37 15837 15842 2-s2.0-70349448718 10.1073/pnas.0903419106
10. Jansen T., Daiber A., Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase? Frontiers in Pharmacology 2012 3 article 30
11. Wegiel B., Otterbein L. E., Go green: the anti-inflammatory effects of biliverdin reductase. Frontiers in Pharmacology 2012 3 article 47
12. Bulmer A. C., Coombes J. S., Blanchfield J. T., Toth I., Fassett R. G., Taylor S. M., Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. British Journal of Pharmacology 2011 164 1857 1870 10.1111/j.1476-5381.2011.01413.x
13. Mccoubrey W. K., Huang T. J., Maines M. D., Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. European Journal of Biochemistry 1997 247 2 725 732 2-s2.0-8544246393
14. Hayashi S., Omata Y., Sakamoto H., Higashimoto Y., Hara T., Sagara Y., Noguchi M., Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 2004 336 2 241 250 2-s2.0-3042799349 10.1016/j.gene.2004.04.002
15. Parfenova H., Leffler C. W., Cerebroprotective functions of HO-2. Current Pharmaceutical Design 2008 14 5 443 453 2-s2.0-42049096126 10.2174/ 138161208783597380
16. Shibahara S., Han F., Li B., Takeda K., Hypoxia and heme oxygenases: oxygen sensing and regulation of expression. Antioxidants & Redox Signaling 2007 9 12 2209 2225 2-s2.0-35848933247 10.1089/ars.2007.1784
17. Arosio P., Levi S., Ferritin, iron homeostasis, and oxidative damage. Free Radical Biology and Medicine 2002 33 4 457 463 2-s2.0-0037101879 10.1016/S0891-5849(02)00842-0
18. Hsu L. L., Champion H. C., Campbell-Lee S. A., Bivalacqua T. J., Manci E. A., Diwan B. A., Schimel D. M., Cochard A. E., Wang X., Schechter A. N., Noguchi C. T., Gladwin M. T., Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007 109 7 3088 3098 2-s2.0-33947605915 10.1182/blood-2006-08-039438
19. Lee M. T., Rosenzweig E. B., Cairo M. S., Pulmonary hypertension in sickle cell disease. Clinical Advances in Hematology and Oncology 2007 5 8 585 653 2-s2.0-34848825033
20. Hill A., Sapsford R. J., Scally A., Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. British Journal of Haematology 2012 158 3 409 414 10.1111/j.1365-2141.2012.09166.x
21. Crary S. E., Ramaciotti C., Buchanan G. R., Prevalence of pulmonary hypertension in hereditary spherocytosis. American Journal of Hematology 2011 86 12 E73 E76 10.1002/ajh.22182
22. Ishigaki K., Takizawa Y., Maruyama J., Setoguchi K., Pulmonary thrombotic microangiopathic hemolytic anemia treated successfully with anticoagulant monotherapy. Internal Medicine 2010 49 12 1217 1220 2-s2.0-77954011357 10.2169/internalmedicine.49.3315
23. Bachmeyer C., Khalil A., Kerrou K., Girot R., Gounant V., Idiopathic pulmonary arterial hypertension in a patient with pyruvate kinase deficiency and paravertebral extramedullary hematopoiesis. Annals of Hematology 2009 88 6 603 605 2-s2.0-67651053275 10.1007/s00277-008-0644-z
24. Janka J. J., Koita O. A., Traoré B., Traoré J. M., Mzayek F., Sachdev V., Wang X., Sanogo K., Sangaré L., Masur L., Masur H., Kato G. J., Gladwin M. T., Krogstad D. J., Increased pulmonary pressures and myocardial wall stress in children with severe malaria. Journal of Infectious Diseases 2010 202 5 791 800 2-s2.0-77955679158 10.1086/655225
25. Taksande A., Prabhu S., Venkatesh S., Cardiovascular aspect of beta-thalassaemia. Cardiovascular & Hematological Agents in Medicinal Chemistry 2012 10 1 25 30 10.2174/187152512799201172
26. Vlahos A. P., Koutsouka F. P., Papamichael N. D., Determinants of pulmonary hypertension in patients with Beta-thalassemia major and normal ventricular function. Acta Haematologica 2012 128 124 129 10.1159/000338825
27. Smiers F. J., Krishnamurti L., Lucarelli G., Hematopoietic stem cell transplantation for hemoglobinopathies: current practice and emerging trends. Pediatric Clinics of North America 2010 57 1 181 205 2-s2.0-77951137730 10.1016/j.pcl.2010.01.003
28. Olney R. S., Preventing morbidity and mortality from sickle cell disease: a public health perspective. American Journal of Preventive Medicine 1999 16 2 116 121 2-s2.0-0033024332 10.1016/S0749-3797(98)00140-8
29. Balla J., Vercellotti G. M., Jeney V., Yachie A., Varga Z., Eaton J. W., Balla G., Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Molecular Nutrition and Food Research 2005 49 11 1030 1043 2-s2.0-28444444498 10.1002/mnfr.200500076
30. Jeney V., Balla J., Yachie A., Varga Z., Vercellotti G. M., Eaton J. W., Balla G., Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002 100 3 879 887 2-s2.0-0036682472 10.1182/blood.V100.3.879
31. Figueiredo R. T., Fernandez P. L., Mourao-Sa D. S., Porto B. N., Dutra F. F., Alves L. S., Oliveira M. F., Oliveira P. L., Graça-Souza A. V., Bozza M. T., Characterization of heme as activator of toll-like receptor 4. Journal of Biological Chemistry 2007 282 28 20221 20229 2-s2.0-34547120742 10.1074/jbc.M610737200
32. Kumar S., Bandyopadhyay U., Free heme toxicity and its detoxification systems in human. Toxicology Letters 2005 157 3 175 188 2-s2.0-19444386445 10.1016/j.toxlet.2005.03.004
33. Morris C. R., Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology 2008 177 185 10.1182/asheducation-2008.1.177 2-s2.0-65949124657
34. Akinsheye I., Klings E. S., Sickle cell anemia and vascular dysfunction: the nitric oxide connection. Journal of Cellular Physiology 2010 224 3 620 625 2-s2.0-77954599927 10.1002/jcp.22195
35. Aslan M., Freeman B. A., Redox-dependent impairment of vascular function in sickle cell disease. Free Radical Biology and Medicine 2007 43 11 1469 1483 2-s2.0-35348950927 10.1016/j.freeradbiomed.2007.08.014
36. de Franceschi L., Cappellini M. D., Olivieri O., Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis 2011 37 3 226 236 2-s2.0-79953662398 10.1055/s-0031-1273087
37. Hahalis G., Kremastinos D. T., Terzis G., Kalogeropoulos A. P., Chrysanthopoulou A., Karakantza M., Kourakli A., Adamopoulos S., Tselepis A. D., Grapsas N., Siablis D., Zoumbos N. C., Alexopoulos D., Global vasomotor dysfunction and accelerated vascular aging in β -thalassemia major. Atherosclerosis 2008 198 2 448 457 2-s2.0-43949122545 10.1016/j.atherosclerosis. 2007.09.030
38. Pober J. S., Min W., Bradley J. R., Mechanisms of endothelial dysfunction, injury, and death. Annual Review of Pathology 2009 4 71 95 2-s2.0-66149102423 10.1146/annurev.pathol.4.110807.092155
39. 2 on cell death, reactive oxygen species and glutathione levels in calf pulmonary artery and human umbilical vein endothelial cells. International Journal of Molecular Medicine 2013 31 471 476
40. Jenkins N. T., Padilla J., Boyle L. J., Credeur D. P., Laughlin M. H., Fadel P. J., Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium. Hypertension 2013 61 615 621 10.1161/HYPERTENSIONAHA.111.00561
41. Hirase T., Node K., Endothelial dysfunction as a cellular mechanism for vascular failure. American Journal of Physiology 2012 302 H499 H505 10.1152/ajpheart.00325.2011
42. Belcher J. D., Mahaseth H., Welch T. E., Vilback A. E., Sonbol K. M., Kalambur V. S., Bowlin P. R., Bischof J. C., Hebbel R. P., Vercellotti G. M., Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. American Journal of Physiology 2005 288 6 H2715 H2725 2-s2.0-21144440415 10.1152/ajpheart.00986.2004
43. Belcher J. D., Mahaseth H., Welch T. E., Otterbein L. E., Hebbel R. P., Vercellotti G. M., Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. Journal of Clinical Investigation 2006 116 3 808 816 2-s2.0-33644649611 10.1172/JCI26857
44. Hovav T., Goldfarb A., Artmann G., Yedgar S., Barshtein G., Enhanced adherence of β -thalassaemic erythrocytes to endothelial cells. British Journal of Haematology 1999 106 1 178 181 2-s2.0-0032818059 10.1046/j.1365-2141. 1999.01489.x
45. Tabima D. M., Frizzell S., Gladwin M. T., Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radical Biology and Medicine 2012 52 9 1970 1986 10.1016/j.freeradbiomed.2012.02.041
46. Stoyanova E., Trudel M., Felfly H., Lemsaddek W., Garcia D., Cloutier G., Vascular endothelial dysfunction in β -thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO. PLoS One 2012 7 e38089
47. Yetik-Anacak G., Catravas J. D., Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascular Pharmacology 2006 45 5 268 276 2-s2.0-33751104760 10.1016/j.vph.2006.08.002
48. Qian H., Neplioueva V., Shetty G. A., Channon K. M., George S. E., Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 1999 99 23 2979 2982 2-s2.0-0033564035
49. Ferroni P., Vazzana N., Riondino S., Cuccurullo C., Guadagni F., Davì G., Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 2012 17 10 1447 1485 10.1089/ars.2011.4324
50. Sudano I., Roas S., Noll G., Vascular abnormalities in essential hypertension. Current Pharmaceutical Design 2011 17 28 3039 3044 10.2174/138161211798157766
51. Wood K. C., Hsu L. L., Gladwin M. T., Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radical Biology and Medicine 2008 44 8 1506 1528 2-s2.0-41549136868 10.1016/j.freeradbiomed.2008.01.008
52. Kaul D. K., Hebbel R. P., Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. The Journal of Clinical Investigation 2000 106 3 411 420 10.1172/JCI9225
53. Maley J. H., Lasker G. F., Kadowitz P. J., Nitric oxide and disorders of the erythrocyte: emerging roles and therapeutic targets. Cardiovascular and Hematological Disorders Drug Targets 2010 10 4 284 291 2-s2.0-79953842951
54. Abboud M. R., Musallam K. M., Sickle cell disease at the dawn of the molecular era. Hemoglobin 2009 33 supplement 1 S93 S106 2-s2.0-73949134236 10.3109/03630260903347617
55. Kato G. J., Taylor J. G., Pleiotropic effects of intravascular haemolysis on vascular homeostasis. British Journal of Haematology 2010 148 5 690 701 2-s2.0-76449093221 10.1111/j.1365-2141.2009.08004.x
56. Mustajoki P., Nordmann Y., Early administration of heme arginate for acute porphyric attacks. Archives of Internal Medicine 1993 153 17 2004 2008 2-s2.0-0027235754 10.1001/archinte.153.17.2004
57. Timonen T. T. T., Kauma H., Therapeutic effect of heme arginate in myelodysplastic syndromes. European Journal of Haematology 1992 49 5 234 238 2-s2.0-0027043120
58. Park J. W., Piknova B., Huang P. L., Noguchi C. T., Schechter A. N., Effect of blood nitrite and nitrate levels on murine platelet function. PLoS One 2013 8 e55699
59. Wanstall J. C., Homer K. L., Doggrell S. A., Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Current Vascular Pharmacology 2005 3 1 41 53 2-s2.0-11844277081 10.2174/1570161052773933
60. Belcher J. D., Marker P. H., Weber J. P., Hebbel R. P., Vercellotti G. M., Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000 96 7 2451 2459 2-s2.0-0034307274
61. Osarogiagbon U. R., Choong S., Belcher J. D., Vercellotti G. M., Paller M. S., Hebbel R. P., Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000 96 1 314 320 2-s2.0-0034235705
62. Kaul D. K., Liu X. D., Zhang X., Ma L., Hsia C. J. C., Nagel R. L., Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants. American Journal of Physiology 2006 291 1 H167 H175 2-s2.0-33745712683 10.1152/ajpheart.01096.2005
63. Wu B. J., Chen K., Barter P. J., Rye K. A., Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 2012 125 150 158 10.1161/CIRCULATIONAHA.111.053108
64. Gentile S., Gentile F., Hypersideremic and hyperbilirubinemic effect of nicotinic acid in patients with Gilbert's syndrome. Hepato-Gastroenterology 1987 34 4 152 154 2-s2.0-0023226408
65. Niihara Y., Zerez C. R., Akiyama D. S., Tanaka K. R., Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. American Journal of Hematology 1998 58 117 121
66. Niihara Y., Matsui N. M., Shen Y. M., Akiyama D. A., Johnson C. S., Sunga M. A., Magpayo J., Embury S. H., Kalra V. K., Cho S. H., Tanaka K. R., L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disorders 2005 5 article 4 2-s2.0-27544476504 10.1186/1471-2326-5-4
67. Morris C. R., Suh J. H., Hagar W., Larkin S., Bland D. A., Steinberg M. H., Vichinsky E. P., Shigenaga M., Ames B., Kuypers F. A., Klings E. S., Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008 111 1 402 410 2-s2.0-38049129666 10.1182/blood-2007-04-081703
68. den Hartog G. J. M., Boots A. W., Adam-Perrot A., Brouns F., Verkooijen I. W. C. M., Weseler A. R., Haenen G. R. M. M., Bast A., Erythritol is a sweet antioxidant. Nutrition 2010 26 4 449 458 2-s2.0-77349122089 10.1016/j.nut.2009. 05.004
69. Hebbel R. P., Vercellotti G. M., Pace B. S., Solovey A. N., Kollander R., Abanonu C. F., Nguyen J., Vineyard J. V., Belcher J. D., Abdulla F., Osifuye S., Eaton J. W., Kelm R. J., Slungaard A., The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 2010 115 12 2483 2490 2-s2.0-77950549033 10.1182/blood-2009-02-204990
70. Finnegan E. M., Barabino G. A., Liu X. D., Chang H. Y., Jonczyk A., Kaul D. K., Small-molecule cyclic α V β 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion. American Journal of Physiology 2007 293 2 H1038 H1045 2-s2.0-34547904664 10.1152/ajpheart.01054.2006
71. Gutsaeva D. R., Parkerson J. B., Yerigenahally S. D., Kurz J. C., Schaub R. G., Ikuta T., Head C. A., Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011 117 2 727 735 2-s2.0-78751507531 10.1182/blood-2010-05-285718
72. Boretti F. S., Buehler P. W., D'Agnillo F., Kluge K., Glaus T., Butt O. I., Jia Y., Goede J., Pereira C. P., Maggiorini M., Schoedon G., Alayash A. I., Schaer D. J., Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. Journal of Clinical Investigation 2009 119 8 2271 2280 2-s2.0-68849086892 10.1172/JCI39115
73. de Franceschi L., Baron A., Scarpa A., Adrie C., Janin A., Barbi S., Kister J., Rouyer-Fessard P., Corrocher R., Leboulch P., Beuzard Y., Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 2003 102 3 1087 1096 2-s2.0-0043245821 10.1182/blood-2002-07-2135
74. de Franceschi L., Malpeli G., Scarpa A., Janin A., Muchitsch E. M., Roncada P., Leboeuf C., Corrocher R., Beuzard Y., Brugnara C., Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. American Journal of Physiology 2006 291 3 L457 L465 2-s2.0-33748416055 10.1152/ajplung.00462.2005
75. Kaul D. K., Zhang X., Dasgupta T., Fabry M. E., Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. American Journal of Physiology 2008 295 1 H39 H47 2-s2.0-49849101277 10.1152/ajpheart.00162.2008
76. Morris C. R., New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. Treatments in Respiratory Medicine 2006 5 1 31 45 2-s2.0-30944435247 10.2165/00151829- 200605010-00003
77. Benza R. L., Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung 2008 186 4 247 254 2-s2.0-47549104449 10.1007/s00408-008-9092-8
78. Silverman T. A., Weiskopf R. B., Hemoglobin-based oxygen carriers: current status and future directions. Transfusion 2009 49 11 2495 2515 2-s2.0-70449127973 10.1111/j.1537-2995.2009.02356.x
79. Li T., Tian H., Zhao Y., Heme oxygenase-1 inhibits progression and destabilization of vulnerable plaques in a rabbit model of atherosclerosis. European Journal of Pharmacology 2011 672 1-3 143 152 10.1016/j.ejphar.2011.09. 188
80. Tsui T. Y., Wu X., Lau C. K., Ho D. W. Y., Xu T., Siu Y. T., Fan S. T., Prevention of chronic deterioration of heart allograft by recombinant adeno-associated virus-mediated heme oxygenase-1 gene transfer. Circulation 2003 107 20 2623 2629 2-s2.0-0037674918
81. Araujo J. A., Meng L., Tward A. D., Hancock W. W., Zhai Y., Lee A., Ishikawa K., Iyer S., Buelow R., Busuttil R. W., Shih D. M., Lusis A. J., Kupiec-Weglinski J. W., Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. Journal of Immunology 2003 171 3 1572 1580 2-s2.0-0042346047
82. Jansen T., Hortmann M., Oelze M., Opitz B., Steven S., Schell R., Knorr M., Karbach S., Schuhmacher S., Wenzel P., Münzel T., Daiber A., Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. Journal of Molecular and Cellular Cardiology 2010 49 2 186 195 2-s2.0-77953704443 10.1016/j.yjmcc.2010.04.011
83. Nath K. A., d'Uscio L. V., Juncos J. P., Croatt A. J., Manriquez M. C., Pittock S. T., Katusic Z. S., An analysis of the DOCA-salt model of hypertension in HO-1-/- mice and the Gunn rat. American Journal of Physiology 2007 293 1 H333 H342 2-s2.0-34547129080 10.1152/ajpheart.00870.2006
84. Belcher J. D., Vineyard J. V., Bruzzone C. M., Chen C., Beckman J. D., Nguyen J., Steer C. J., Vercellotti G. M., Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. Journal of Molecular Medicine 2010 88 7 665 675 2-s2.0-77954541322 10.1007/s00109-010-0613-6
85. Belcher J. D., Beckman J. D., Balla G., Balla J., Vercellotti G., Heme degradation and vascular injury. Antioxidants & Redox Signaling 2010 12 2 233 248 2-s2.0-77949496427 10.1089/ars.2009.2822
86. Li Q., Guo Y., Ou Q., Wu W. J., Chen N., Zhu X., Tan W., Yuan F., Dawn B., Luo L., Hunt G. N., Bolli R., Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. Basic Research in Cardiology 2011 106 6 1367 1377 2-s2.0-79960487611 10.1007/s00395-011-0208-6
87. Lipiski M., Deuel J. W., Baek J. H., Engelsberger W. R., Buehler P. W., Schaer D. J., Human Hp1-1 and Hp2-2 phenotype-specific haptoglobin therapeutics are both effective in vitro and in guinea pigs to attenuate hemoglobin toxicity. Antioxidants & Redox Signaling 2013 10.1089/ars.2012.5089
88. Baek J. H., D'Agnillo F., Vallelian F., Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. The Journal of Clinical Investigation 2012 122 4 1444 1458 10.1172/JCI59770
89. Morris C. M., Candy J. M., Edwardson J. A., Bloxham C. A., Smith A., Evidence for the localization of haemopexin immunoreactivity in neurones in the human brain. Neuroscience Letters 1993 149 2 141 144 2-s2.0-0027391548 10.1016/0304-3940(93)90756-B
90. Morello N., Tonoli E., Logrand F., Fiorito V., Fagoonee S., Turco E., Silengo L., Vercelli A., Altruda F., Tolosano E., Haemopexin affects iron distribution and ferritin expression in mouse brain. Journal of Cellular and Molecular Medicine 2009 13 10 4192 4204 2-s2.0-77449150120 10.1111/j.1582-4934. 2008.00611.x
91. Takahashi N., Takahashi Y., Putnam F. W., Structure of human hemopexin: O-glycosyl and N-glycosyl sites and unusual clustering of tryptophan residues. Proceedings of the National Academy of Sciences of the United States of America 1984 81 7 2021 2025 2-s2.0-0002656925
92. Paoli M., Anderson B. F., Baker H. M., Morgan W. T., Smith A., Baker E. N., Crystal structure of hemopexin reveals a novel high-affinity heme site formed between two β -propeller domains. Nature Structural Biology 1999 6 10 926 931 2-s2.0-0032825215 10.1038/13294
93. Tolosano E., Altruda F., Hemopexin: structure, function, and regulation. DNA and Cell Biology 2002 21 4 297 306 2-s2.0-0036259938 10.1089/ 104454902753759717
94. Satoh H., Nagae Y., Immenschuh S., Satoh T., Muller-Eberhard U., Identification of a liver preference enhancer element of the rat hemopexin gene and its interaction with nuclear factors. Journal of Biological Chemistry 1994 269 9 6851 6858 2-s2.0-0028173628
95. Immenschuh S., Nagae Y., Satoh H., Baumann H., Muller-Eberhard U., The rat and human hemopexin genes contain an identical interleukin-6 response element that is not a target of CAAT enhancer-binding protein isoforms. Journal of Biological Chemistry 1994 269 17 12654 12661 2-s2.0-0028222522
96. Immenschuh S., Song D. X., Satoh H., Muller-Eberhard U., The type II hemopexin interleukin-6 response element predominates the transcriptional regulation of the hemopexin acute phase responsiveness. Biochemical and Biophysical Research Communications 1995 207 1 202 208 2-s2.0-0028908898 10.1006/bbrc.1995.1173
97. Tolosano E., Hirsch E., Patrucco E., Camaschella C., Navone R., Silengo L., Altruda F., Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood 1999 94 11 3906 3914 2-s2.0-0033485566
98. Tolosano E., Fagoonee S., Hirsch E., Berger F. G., Baumann H., Silengo L., Altruda F., Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002 100 12 4201 4208 2-s2.0-0036893587 10.1182/blood-2002-04-1270
99. Vinchi F., de Franceschi L., Ghigo A., Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013 127 12 1317 1329 10.1161/CIRCULATIONAHA.112.130179
100. Liang X., Lin T., Sun G., Beasley-Topliffe L., Cavaillon J. M., Warren H. S., Hemopexin down-regulates LPS-induced proinflammatory cytokines from macrophages. Journal of Leukocyte Biology 2009 86 2 229 235 2-s2.0-69449086963 10.1189/jlb.1208742
101. Lin T., Kwak Y. H., Sammy F., He P., Thundivalappil S., Sun G., Chao W., Warren H. S., Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. Journal of Infectious Diseases 2010 202 4 624 632 2-s2.0-77954699484 10.1086/654929
102. Cheung P. K., Klok P. A., Baller J. F. W., Bakker W. W., Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney International 2000 57 4 1512 1520 2-s2.0-0034087572 10.1046/j.1523-1755. 2000.00996.x
103. Bakker W. W., Borghuis T., Harmsen M. C., Van Den Berg A., Kema I. P., Niezen K. E., Kapojos J. J., Protease activity of plasma hemopexin. Kidney International 2005 68 2 603 610 2-s2.0-26944501268 10.1111/j.1523-1755.2005. 00438.x
104. Hentze M. W., Muckenthaler M. U., Galy B., Camaschella C., Two to tango: regulation of mammalian iron metabolism. Cell 2010 142 1 24 38 2-s2.0-77954249308 10.1016/j.cell.2010.06.028